Dimethyl-celecoxib (DMC), a derivative of celecoxib that lacks cyclooxygenase-2-inhibitory function, potently mimics the anti-tumor effects of celecoxib on Burkitt's lymphoma in vitro and in vivo.
about
Targeting KSHV/HHV-8 latency with COX-2 selective inhibitor nimesulide: a potential chemotherapeutic modality for primary effusion lymphomaCOX-2 inhibition is neither necessary nor sufficient for celecoxib to suppress tumor cell proliferation and focus formation in vitroDirect non-cyclooxygenase-2 targets of celecoxib and their potential relevance for cancer therapyCadherin-11 in poor prognosis malignancies and rheumatoid arthritis: common target, common therapiesChemophototherapy: An Emerging Treatment Option for Solid TumorsInhibition mechanism of the intracellular transporter Ca2+-pump from sarco-endoplasmic reticulum by the antitumor agent dimethyl-celecoxibThe influence of Cox-2 and bioactive lipids on hematological cancers.Celecoxib analogs that lack COX-2 inhibitory function: preclinical development of novel anticancer drugs.Defects in mouse nephrogenesis induced by selective and non-selective cyclooxygenase-2 inhibitorsEndoplasmic reticulum stress in the peripheral nervous system is a significant driver of neuropathic pain.Kv7 potassium channels in airway smooth muscle cells: signal transduction intermediates and pharmacological targets for bronchodilator therapy.Targeting cyclooxygenase-2 in hematological malignancies: rationale and promiseEndoplasmic reticulum stress: its role in disease and novel prospects for therapy.Celecoxib and 2,5-dimethylcelecoxib inhibit intestinal cancer growth by suppressing the Wnt/β-catenin signaling pathwayCOX-Independent Mechanisms of Cancer Chemoprevention by Anti-Inflammatory Drugs.Celecoxib promotes c-FLIP degradation through Akt-independent inhibition of GSK3.Celecoxib sensitizes gastric cancer to rapamycin via inhibition of the Cbl-b-regulated PI3K/Akt pathway.Molecular characterization of the boron adducts of the proteasome inhibitor bortezomib with epigallocatechin-3-gallate and related polyphenols.Effects of celecoxib and ibuprofen on metabolic disorders induced by Walker-256 tumor in rats.Concurrent targeting of eicosanoid receptor 1/eicosanoid receptor 4 receptors and COX-2 induces synergistic apoptosis in Kaposi's sarcoma-associated herpesvirus and Epstein-Barr virus associated non-Hodgkin lymphoma cell lines.Sulindac sulfide inhibits sarcoendoplasmic reticulum Ca2+ ATPase, induces endoplasmic reticulum stress response, and exerts toxicity in glioma cells: relevant similarities to and important differences from celecoxib.Combination of celecoxib (Celebrex®) and CD19 CAR-redirected CTL immunotherapy for the treatment of B-cell non-Hodgkin's lymphomas.Celecoxib inhibits proliferation and survival of chronic myelogeous leukemia (CML) cells via AMPK-dependent regulation of β-catenin and mTORC1/2.Downregulation of survivin expression and concomitant induction of apoptosis by celecoxib and its non-cyclooxygenase-2-inhibitory analog, dimethyl-celecoxib (DMC), in tumor cells in vitro and in vivoThe ER stress inducer DMC enhances TRAIL-induced apoptosis in glioblastoma.Lymphoblastic T-cell lymphoma in mice is unaffected by Celecoxib as single agent or in combination with cyclophosphamide.2,5-Dimethylcelecoxib prevents pressure-induced left ventricular remodeling through GSK-3 activation.Celecoxib exerts protective effects in the vascular endothelium via COX-2-independent activation of AMPK-CREB-Nrf2 signalling.
P2860
Q21135231-6EEFE36B-D68B-4841-96FA-DA54822652B5Q21245723-7CA0E25E-D70A-47D2-9C9D-2EA899F1D09BQ24653348-FF3BB147-51B3-4120-A068-0FD1284F217CQ28237085-77FE6748-AC74-488E-9A8C-DEC5EF896F96Q28468315-A18848AE-139F-40F1-9DF2-2C283BF93C52Q28540515-6C77879C-A025-4764-9A6C-D310FA583D99Q33688673-07110869-0DA0-40CF-9A04-F5FBC05F0FF0Q34743086-5A671886-CCCA-40EE-BA4A-F554B8CFADE3Q35089858-311DB3E8-3209-40F6-A90D-8D38AA4027E4Q35895730-C41D2D60-8320-491E-B4F2-C220B33AF5A7Q35950205-E25A4BCE-DD21-47A0-9D41-11FF44B4BC06Q37239890-6EA94465-C7D2-4EF2-9BF6-80788E5A1784Q37288073-740A54E3-4ED2-418C-BFED-EB972E2F8AD4Q37611657-04F2F06A-A5AC-4B56-870D-37FDC692B479Q38123175-579C309F-828E-446A-B85E-251C996B979EQ38609949-0368B5BC-5049-4E8D-B3E3-3B981C847017Q38907631-F1FA9CF4-D889-45F7-A58C-5758F7CC34B2Q38911003-028D4F9A-8F52-4FCA-961D-760D1F0CEFFBQ38943695-1FCDF57E-131C-4C85-B690-0861E57E1285Q39176686-03F5C231-2F45-4EEA-9E82-5BB791DE9370Q39218093-5DD87EED-A1D6-4012-AB6D-3E64D186B76AQ41270773-68A31955-8FB2-49D9-A1A5-438D15877341Q42316726-5F85FE3A-C223-465D-8372-A3C30262F738Q42407745-8965559D-B31E-47C2-936D-5F03BCFD0A55Q42968961-91310AFB-8B61-4718-AD84-AE3323288B12Q45951584-9ADB3384-83CE-45F3-B742-19649C5E2396Q47388691-F6E67605-4205-4ECD-B3E1-B44699F5E725Q54115193-4333854E-A25A-46AE-BE4B-6C31CD270761
P2860
Dimethyl-celecoxib (DMC), a derivative of celecoxib that lacks cyclooxygenase-2-inhibitory function, potently mimics the anti-tumor effects of celecoxib on Burkitt's lymphoma in vitro and in vivo.
description
2005 nî lūn-bûn
@nan
2005 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Dimethyl-celecoxib (DMC), a de ...... lymphoma in vitro and in vivo.
@ast
Dimethyl-celecoxib (DMC), a de ...... lymphoma in vitro and in vivo.
@en
Dimethyl-celecoxib (DMC), a de ...... lymphoma in vitro and in vivo.
@nl
type
label
Dimethyl-celecoxib (DMC), a de ...... lymphoma in vitro and in vivo.
@ast
Dimethyl-celecoxib (DMC), a de ...... lymphoma in vitro and in vivo.
@en
Dimethyl-celecoxib (DMC), a de ...... lymphoma in vitro and in vivo.
@nl
prefLabel
Dimethyl-celecoxib (DMC), a de ...... lymphoma in vitro and in vivo.
@ast
Dimethyl-celecoxib (DMC), a de ...... lymphoma in vitro and in vivo.
@en
Dimethyl-celecoxib (DMC), a de ...... lymphoma in vitro and in vivo.
@nl
P2093
P356
P1476
Dimethyl-celecoxib (DMC), a de ...... lymphoma in vitro and in vivo
@en
P2093
Adel Kardosh
Axel H Schönthal
Florence M Hofman
Jasim Uddin
Thomas C Chen
Weijun Wang
P304
P356
10.4161/CBT.4.5.1699
P577
2005-05-05T00:00:00Z